 |
|
|
| |
Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children
|
| |
| |
EASL 2024 June 5-8 Milan Italy
Maria Pokorska-Spiewak1, Ewa Talarek2, Anna Dobrzeniecka3, Malgorzata Aniszewska2, Magdalena Pluta2, Magdalena Marczynska2. 1Medical University of Warsaw, Regional Hospital of Infectious Diseases, Warsaw, Poland; 2Medical University of Warsaw, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland; 3Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland
|
| |
|
|
|
|
|
